                         SEQUENCE LISTING

<110>  BRIM Biotechnology, Inc.
 
<120>  METHOD FOR SUPPRESSION OF HEPAPITIS B VIRUS REPLICATION 
       AND HEPAPITIS B VIRUS SURFACE ANTIGEN SECRETION

<130>  BM141-HBV

<150>  US 62/716,375
<151>  2018-09-09

<160>  34    

<170>  PatentIn version 3.5

<210>  1
<211>  5
<212>  PRT
<213>  Artificial

<220>
<223>  H-CDR1

<400>  1

Asn Tyr Trp Ile Asn 
1               5   


<210>  2
<211>  10
<212>  PRT
<213>  artificial

<220>
<223>  H-CDR1

<400>  2

Gly Phe Ser Leu Thr Ser Asn Ser Ile Ser 
1               5                   10  


<210>  3
<211>  17
<212>  PRT
<213>  artificial

<220>
<223>  H-CDR2

<400>  3

Asn Ile Tyr Pro Ser Asp Thr Tyr Ile Asn His Asn Gln Lys Phe Lys 
1               5                   10                  15      


Asp 
    


<210>  4
<211>  16
<212>  PRT
<213>  artificial

<220>
<223>  H-CDR2

<400>  4

Ala Ile Trp Ser Gly Gly Gly Thr Asp Tyr Asn Ser Asp Leu Lys Ser 
1               5                   10                  15      


<210>  5
<211>  9
<212>  PRT
<213>  artificial

<220>
<223>  H-CDR3

<400>  5

Ser Ala Tyr Ala Asn Tyr Phe Asp Tyr 
1               5                   


<210>  6
<211>  10
<212>  PRT
<213>  artificial

<220>
<223>  H-CDR3

<400>  6

Arg Gly Gly Tyr Pro Tyr Tyr Phe Asp Tyr 
1               5                   10  


<210>  7
<211>  11
<212>  PRT
<213>  artificial

<220>
<223>  L-CDR1

<400>  7

Arg Ala Ser Gln Asn Ile Gly Thr Ser Ile His 
1               5                   10      


<210>  8
<211>  17
<212>  PRT
<213>  artificial

<220>
<223>  L-CDR1

<400>  8

Lys Ser Ser Gln Ser Leu Leu Tyr Ser Glu Asn Gln Glu Asn Tyr Leu 
1               5                   10                  15      


Ala 
    


<210>  9
<211>  7
<212>  PRT
<213>  artificial

<220>
<223>  L-CDR2

<400>  9

Tyr Ala Ser Glu Ser Ile Ser 
1               5           


<210>  10
<211>  7
<212>  PRT
<213>  artificial

<220>
<223>  L-CDR2

<400>  10

Trp Ala Ser Thr Arg Gln Ser 
1               5           


<210>  11
<211>  10
<212>  PRT
<213>  artificial

<220>
<223>  L-CDR3

<400>  11

Gln Gln Ser Asp Ser Trp Pro Thr Leu Thr 
1               5                   10  


<210>  12
<211>  9
<212>  PRT
<213>  artificial

<220>
<223>  L-CDR3

<400>  12

Gln Gln Tyr Tyr Asp Thr Pro Leu Thr 
1               5                   


<210>  13
<211>  118
<212>  PRT
<213>  artificial

<220>
<223>  Heavy chain variable region of the humanized anti-CD11b 
       antibodies-VH1

<400>  13

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Trp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Asn Ile Tyr Pro Ser Asp Thr Tyr Ile Asn His Asn Gln Lys Phe 
    50                  55                  60                  


Lys Asp Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Ser Ala Tyr Ala Asn Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  14
<211>  118
<212>  PRT
<213>  artificial

<220>
<223>  Heavy chain variable region of the humanized anti-CD11b 
       antibodies-VH2

<400>  14

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asn Tyr 
            20                  25                  30          


Trp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Asn Ile Tyr Pro Ser Asp Thr Tyr Ile Asn His Asn Gln Lys Phe 
    50                  55                  60                  


Lys Asp Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Thr Ser Ala Tyr Ala Asn Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  15
<211>  118
<212>  PRT
<213>  artificial

<220>
<223>  Heavy chain variable region of the humanized anti-CD11b 
       antibodies-VH3

<400>  15

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Trp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Asn Ile Tyr Pro Ser Asp Thr Tyr Ile Asn His Asn Gln Lys Phe 
    50                  55                  60                  


Lys Asp Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Ser Ala Tyr Ala Asn Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  16
<211>  118
<212>  PRT
<213>  artificial

<220>
<223>  Heavy chain variable region of the humanized anti-CD11b 
       antibodies-VH4

<400>  16

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Trp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Asn Ile Tyr Pro Ser Asp Thr Tyr Ile Asn His Asn Gln Lys Phe 
    50                  55                  60                  


Lys Asp Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Ser Ala Tyr Ala Asn Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  17
<211>  118
<212>  PRT
<213>  artificial

<220>
<223>  Heavy chain variable region of the humanized anti-CD11b 
       antibodies-VH5

<400>  17

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Val Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Trp Ile Asn Trp Val Gln Gln Ala Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Asn Ile Tyr Pro Ser Asp Thr Tyr Ile Asn His Asn Gln Lys Phe 
    50                  55                  60                  


Lys Asp Arg Val Thr Ile Thr Ala Asp Thr Ser Thr Asp Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Ser Ala Tyr Ala Asn Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Arg 
        115             


<210>  18
<211>  117
<212>  PRT
<213>  artificial

<220>
<223>  Heavy chain variable region of the humanized anti-CD11b 
       antibodies-HC1

<400>  18

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Asn 
            20                  25                  30          


Ser Ile Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Ala Ile Trp Ser Gly Gly Gly Thr Asp Tyr Asn Ser Asp Leu Lys 
    50                  55                  60                  


Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 
65                  70                  75                  80  


Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Gly Gly Tyr Pro Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  19
<211>  117
<212>  PRT
<213>  artificial

<220>
<223>  Heavy chain variable region of the humanized anti-CD11b 
       antibodies-HC2

<400>  19

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gly 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Phe Ser Leu Thr Ser Asn 
            20                  25                  30          


Ser Ile Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Ala Ile Trp Ser Gly Gly Gly Thr Asp Tyr Asn Ser Asp Leu Lys 
    50                  55                  60                  


Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 
65                  70                  75                  80  


Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Gly Gly Tyr Pro Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Met 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  20
<211>  117
<212>  PRT
<213>  artificial

<220>
<223>  Heavy chain variable region of the humanized anti-CD11b 
       antibodies-HC3

<400>  20

Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Phe Ser Leu Thr Ser Asn 
            20                  25                  30          


Ser Ile Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Ala Ile Trp Ser Gly Gly Gly Thr Asp Tyr Asn Ser Asp Leu Lys 
    50                  55                  60                  


Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 
65                  70                  75                  80  


Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Gly Gly Tyr Pro Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  21
<211>  117
<212>  PRT
<213>  artificial

<220>
<223>  Heavy chain variable region of the humanized anti-CD11b 
       antibodies-HC4

<400>  21

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Leu Thr Ser Asn 
            20                  25                  30          


Ser Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Ala Ile Trp Ser Gly Gly Gly Thr Asp Tyr Asn Ser Asp Leu Lys 
    50                  55                  60                  


Ser Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu 
65                  70                  75                  80  


Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Gly Gly Tyr Pro Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  22
<211>  117
<212>  PRT
<213>  artificial

<220>
<223>  Heavy chain variable region of the humanized anti-CD11b 
       antibodies-HC5

<400>  22

Glu Val Gln Leu Val Glu Thr Gly Gly Gly Leu Ile Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Leu Thr Ser Asn 
            20                  25                  30          


Ser Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Ala Ile Trp Ser Gly Gly Gly Thr Asp Tyr Asn Ser Asp Leu Lys 
    50                  55                  60                  


Ser Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu 
65                  70                  75                  80  


Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Gly Gly Tyr Pro Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  23
<211>  108
<212>  PRT
<213>  artificial

<220>
<223>  Light chain variable region of the humanized anti-CD11b 
       antibodies-VL1

<400>  23

Glu Ile Val Leu Thr Gln Ser Pro Asp Phe Gln Ser Val Thr Pro Lys 
1               5                   10                  15      


Glu Lys Val Thr Ile Thr Cys Arg Ala Ser Gln Asn Ile Gly Thr Ser 
            20                  25                  30          


Ile His Trp Tyr Gln Gln Lys Pro Asp Gln Ser Pro Lys Leu Leu Ile 
        35                  40                  45              


Lys Tyr Ala Ser Glu Ser Ile Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Glu Ala 
65                  70                  75                  80  


Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Asp Ser Trp Pro Thr 
                85                  90                  95      


Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105             


<210>  24
<211>  108
<212>  PRT
<213>  artificial

<220>
<223>  Light chain variable region of the humanized anti-CD11b 
       antibodies-VL2

<400>  24

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Asn Ile Gly Thr Ser 
            20                  25                  30          


Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Asp Ser Trp Pro Thr 
                85                  90                  95      


Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
            100                 105             


<210>  25
<211>  108
<212>  PRT
<213>  artificial

<220>
<223>  Light chain variable region of the humanized anti-CD11b 
       antibodies-VL3

<400>  25

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asn Ile Gly Thr Ser 
            20                  25                  30          


Ile His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Ala Ser Glu Ser Ile Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Asp Ser Trp Pro Thr 
                85                  90                  95      


Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105             


<210>  26
<211>  108
<212>  PRT
<213>  artificial

<220>
<223>  Light chain variable region of the humanized anti-CD11b 
       antibodies-VL4

<400>  26

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Asn Ile Gly Thr Ser 
            20                  25                  30          


Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Asp Ser Trp Pro Thr 
                85                  90                  95      


Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105             


<210>  27
<211>  108
<212>  PRT
<213>  artificial

<220>
<223>  Light chain variable region of the humanized anti-CD11b 
       antibodies-VL5

<400>  27

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Asn Ile Gly Thr Ser 
            20                  25                  30          


Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Asp Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Asp Ser Trp Pro Thr 
                85                  90                  95      


Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
            100                 105             


<210>  28
<211>  113
<212>  PRT
<213>  artificial

<220>
<223>  Light chain variable region of the humanized anti-CD11b 
       antibodies-LC1

<400>  28

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser 
            20                  25                  30          


Glu Asn Gln Glu Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 
        35                  40                  45              


Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Gln Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln 
                85                  90                  95      


Tyr Tyr Asp Thr Pro Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile 
            100                 105                 110         


Lys 
    


<210>  29
<211>  113
<212>  PRT
<213>  artificial

<220>
<223>  Light chain variable region of the humanized anti-CD11b 
       antibodies-LC2

<400>  29

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser 
            20                  25                  30          


Glu Asn Gln Glu Asn Tyr Leu Ala Trp Tyr Leu Gln Lys Pro Gly Gln 
        35                  40                  45              


Ser Pro Gln Leu Leu Ile Tyr Trp Ala Ser Thr Arg Gln Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys 
65                  70                  75                  80  


Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln 
                85                  90                  95      


Tyr Tyr Asp Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile 
            100                 105                 110         


Lys 
    


<210>  30
<211>  113
<212>  PRT
<213>  artificial

<220>
<223>  Light chain variable region of the humanized anti-CD11b 
       antibodies-LC3

<400>  30

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Ser Val Thr Pro Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser 
            20                  25                  30          


Glu Asn Gln Glu Asn Tyr Leu Ala Trp Tyr Leu Gln Lys Pro Gly Gln 
        35                  40                  45              


Ser Pro Gln Leu Leu Ile Tyr Trp Ala Ser Thr Arg Gln Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys 
65                  70                  75                  80  


Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln 
                85                  90                  95      


Tyr Tyr Asp Thr Pro Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile 
            100                 105                 110         


Lys 
    


<210>  31
<211>  113
<212>  PRT
<213>  artificial

<220>
<223>  Light chain variable region of the humanized anti-CD11b 
       antibodies-LC4

<400>  31

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser 
            20                  25                  30          


Glu Asn Gln Glu Asn Tyr Leu Ala Trp Phe Gln Gln Arg Pro Gly Gln 
        35                  40                  45              


Ser Pro Arg Arg Leu Ile Tyr Trp Ala Ser Thr Arg Gln Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys 
65                  70                  75                  80  


Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln 
                85                  90                  95      


Tyr Tyr Asp Thr Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile 
            100                 105                 110         


Lys 
    


<210>  32
<211>  113
<212>  PRT
<213>  artificial

<220>
<223>  Light chain variable region of the humanized anti-CD11b 
       antibodies-LC5

<400>  32

Asp Ile Val Met Thr Gln Thr Pro Leu Ser Ser Pro Val Thr Leu Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser 
            20                  25                  30          


Glu Asn Gln Glu Asn Tyr Leu Ala Trp Leu Gln Gln Arg Pro Gly Gln 
        35                  40                  45              


Pro Pro Arg Leu Leu Ile Tyr Trp Ala Ser Thr Arg Gln Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys 
65                  70                  75                  80  


Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln 
                85                  90                  95      


Tyr Tyr Asp Thr Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile 
            100                 105                 110         


Lys 
    


<210>  33
<211>  19
<212>  DNA
<213>  artificial

<220>
<223>  HBx forward primer

<400>  33

ccgatccata ctgcggaac                                                19



<210>  34
<211>  21
<212>  DNA
<213>  artificial

<220>
<223>  HBx reverse primer

<400>  34

gcagaggtga agcgaagtgc a                                             21



